Ideaya Biosciences falls on earnings miss as investors await key March data
Biotech posts wider-than-expected loss but strengthens balance sheet with $1.05B cash position ahead of darovasertib trial results
Ideaya Biosciences shares declined in Tuesday trading after the precision medicine oncology company reported a wider-than-expected quarterly loss, even as collaboration revenue surged and executives highlighted a strengthened balance sheet ahead of a critical clinical data readout next month.
The South San Francisco-based company reported a net loss of $94 cents per share for the fourth quarter of 2025, missing analyst expectations of a 55-cent loss, according to the company's earnings announcement. The stock fell 4% to $30.27 following the release, extending a recent decline that has seen shares drop nearly 6% over the past two weeks.
Despite the earnings miss, investors found encouragement in the company's topline performance. Collaboration revenue reached $10.9 million in the quarter, up 56% from $7 million in the same period last year, driven by research and development services under the company's exclusive license agreement with Servier for darovasertib, its lead cancer drug candidate. The full-year revenue jumped to $218.7 million, bolstered by the strategic partnership.
The company's net loss improved 36% year-over-year to $83.3 million, compared to $130.3 million in the prior-year quarter. More importantly for a clinical-stage biotech, Ideaya ended 2025 with approximately $1.05 billion in cash, cash equivalents, and marketable securities—a position executives say will fund operations into 2030.
"We ended 2025 with a strong balance sheet, providing us with financial flexibility to advance our pipeline and key upcoming catalysts," the company stated in its earnings release.
That flexibility is crucial as investors turn their attention to a binary event expected in approximately six weeks. Ideaya said topline progression-free survival data from the registrational Phase 2/3 OptimUM-02 trial of darovasertib in combination with crizotinib for first-line metastatic uveal melanoma should arrive by the last week of March. The trial has already confirmed 130 required PFS events by blinded independent central review.
Uveal melanoma is a rare but aggressive form of eye cancer with limited treatment options. The data readout is intended to support a potential accelerated approval filing in the United States, making it a make-or-break moment for darovasertib and potentially for Ideaya's commercial prospects.
Previous data from a single-arm Phase 1/2 trial showed median progression-free survival of 7.0 months and median overall survival of 21.1 months, compared to historical overall survival of approximately 12 months. The combination demonstrated a confirmed overall response rate of 34% and disease control rate of 90%.
Wall Street analysts remain broadly optimistic despite the earnings disappointment. The stock carries a consensus "Moderate Buy" rating with an average price target of $46.60, according to MarketBeat data, implying roughly 54% upside from current levels. Individual targets range from $30 to $79, with Citizens Securities recently reiterating its "Market Outperform" rating and $45 price target, while UBS initiated coverage with a "Buy" rating and $50 target.
The Servier partnership, announced in September, provided a $210 million upfront payment with potential milestone payments of up to an additional $320 million, significantly extending Ideaya's cash runway. The collaboration covers darovasertib worldwide, with Servier handling commercialization outside the United States.
Beyond the upcoming March readout, Ideaya said darovasertib is anticipated to be in three randomized, Phase 3 registrational trials in uveal melanoma covering metastatic, neoadjuvant, and adjuvant settings by the first half of 2026. Enrollment of approximately 100 HLA*A2-positive metastatic uveal melanoma patients in the single-arm Phase 2 OptimUM-01 trial is expected to be complete by the second quarter of 2026.
For now, investors appear to be taking a wait-and-see approach, selling into the earnings weakness ahead of what could be a defining moment for the company. The $1.05 billion cash position provides a substantial buffer, but in biotech, binary clinical data readouts often trump balance sheet strength in determining near-term stock performance. The last week of March will likely provide the answer.